In the news release, Aduromed (OTC Bulletin Board: ADRM) Elects Kenneth L. Londoner to Board of Directors, issued Wednesday, Nov. 12, by Aduromed Industries, Inc. over PR Newswire, we are advised by the company that the second paragraph, second sentence, should read "raised $8.2 million" rather than "$14.6 million" as originally issued inadvertently. Complete, corrected release follows:



          Aduromed Elects Kenneth L. Londoner to Board of Directors

  Adds Wall Street, Business Development, and Corporate Finance Expertise to
                                    Board

BETHEL, Conn., Nov. 12 /PRNewswire-FirstCall/ -- Aduromed Industries, Inc. (OTC Bulletin Board: ADRM), a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste, today announced that Kenneth L. Londoner has been elected to the Company's board of directors.

Mr. Londoner currently serves as the head of Business Development and Corporate Finance for NewCardio, Inc., a cardiac diagnostic and services company. In this role, he engineered and consummated the process of taking the company public via a reverse merger and raised $8.2 million in a public financing. Previously, he was Co-Founder and Executive Vice President of Safe Ports, LLC and its wholly-owned subsidiary, Carolina Linkages, Inc., a Charleston, S.C.-based port security services and intermodal transportation infrastructure development company. At Safe Ports he raised approximately $7 million in start-up funds, recruited key executives and board members to the company, including Senator Tom Daschle, U.S. Transportation Secretary Norman Mineta, Chuck Raymond CEO of Horizon Shipping and well-known Wall Street analyst Maggie Gilliam. The firm was subsequently sold to the Government of Dubai resulting in a significant return on the company's investment. Previously, he was the founder, CEO and General Partner of Red Coat Capital Management, a U.S. equity long/short hedge fund, which he grew to a peak of $980 million in assets under management. Before opening Red Coat, he was a Vice President and Investment Officer for J. & W. Seligman & Co., one of the oldest and most-respected U.S. mutual fund groups, where he co-managed several successful funds. He began his professional career as a mutual fund accountant for State Street Bank and Trust, Inc. in Boston.

Mr. Joseph Esposito, Chairman of the Board of Directors, commented, "I am thrilled to add a proven leader and a veteran corporate finance expert like Ken Londoner to our board, and I am confident he will prove invaluable to the board and the Company as we develop and execute our strategic plan. He has demonstrated the capability to secure funding for emerging companies, even in challenging environments, and has a track record of creating value for small companies and their shareholders. He will be an excellent addition to the Aduromed board and I look forward to benefiting from his expertise."

Mr. Londoner added, "I am impressed with Aduromed's technology and embrace the vision the Company has for driving growth. The Company's new business model featuring standard containerized systems and multiple acquisition options has great potential to expand the opportunity and allow the company to capture market share and drive significant cash flows. Joe Esposito and his team have solid, proven track records of creating shareholder value and are the ideal group to take this company to the next level. I am excited to have personally invested in the new Aduromed, and also eager to join the board of directors and assist this company in its growth initiatives."

About Aduromed Industries, Inc.

Aduromed Industries, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. Aduromed's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. Aduromed was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on Aduromed can be found at http://www.aduromed.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

SOURCE Aduromed Industries, Inc.